Latest news with #AsstonPharmaceuticals
News18
2 days ago
- Business
- News18
Asston Pharmaceuticals IPO GMP: Issue Gets 61.15x Subscription, To Close Today
Last Updated: The GMP of the Asston Pharmaceuticals IPO stands at 24.39%, indicating strong sentiment among investors. Asston Pharmaceuticals IPO GMP Day 3: The initial public offering of Asston Pharmaceuticals Ltd is going to be closed today, Friday, July 11. The price band of the BSE SME IPO, which aims to raise Rs 27.56 crore, has been fixed at Rs 123 apiece. Till 1:10 pm on the last day of bidding on Friday, the issue received a 61.15 times subscription, garnering bids for 9,12,96,000 shares as against the 14,93,000 shares on offer. The retail and NII participation stood at 67.70x and 114.56x, respectively. The QIB category also received a 9.18x subscription. The IPO's grey market premium (GMP) stood at 24.39%, indicating strong sentiment among investors. The three-day IPO was opened on July 9. Asston Pharmaceuticals Limited, founded in 2019, is a global exporter of FDA-certified pharmaceutical products across diverse therapeutic categories, operating through direct sales and contract manufacturing. Asston Pharmaceuticals IPO GMP Today According to market observers, unlisted shares of Asston Pharmaceuticals Ltd are currently trading at Rs 153 against its upper IPO price of Rs 123. It means a grey market premium or GMP of Rs 30, which is 24.39% over its issue price, indicating strong listing gains. The GMP is based on market sentiments and keeps changing. 'Grey market premium' indicates investors' readiness to pay more than the issue price. The price of the IPO has been fixed at Rs 123 apiece. Its minimum lot size is 1,000. It means investors will have to apply for a minimum of 1,000 shares or in multiple thereof. Retail investors require a minimum capital of Rs 2,30,000 to apply for the IPO. Asston Pharmaceuticals IPO Allotment And Listing Dates The basis of allotment of the Asston Pharmaceuticals IPO will be finalised on Monday, July 14. Shares of Asston Pharmaceuticals Ltd will be listed on the BSE SME platform on July 16. Asston Pharmaceuticals IPO: More Info The IPO, which is a bookbuilding of Rs 27.56 crore, is entirely a fresh issue of 22.41 lakh shares. Asston Pharma's revenue increased by 62% and profit after tax (PAT) rose by 218% between the financial year ending with March 31, 2025 and March 31, 2024. Sobhagya Capital Options Ltd is the book-running lead manager of the Asston Pharmaceuticals IPO, while Maashitla Securities Private Limited is the registrar for the market maker for Asston Pharmaceuticals IPO is JSK Securities and Services Private Limited. view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Economic Times
2 days ago
- Business
- Economic Times
Asston Pharma SME IPO booked over 32 times on Day 3. Check GMP and other details
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The IPO of Asston Pharmaceuticals, a fast-growing exporter of healthcare and pharmaceutical products, has garnered strong investor interest across all categories, with the issue subscribed a massive 32.13 times ahead of its closing on July 11, investors led the surge, subscribing 37.58 times their allotted quota, followed by high-net-worth individuals (HNIs) at 51.40 times. Qualified institutional buyers (QIBs) also showed strong interest, subscribing 7.98 times — underscoring broad-based confidence in the company's growth trajectory and global expansion book-built issue is priced in the range of Rs 115 to Rs 123 per share, with a fixed lot size of 1,000 shares. At the upper end of the price band, the IPO aims to raise Rs 27.56 crore entirely through a fresh issue of 22.41 lakh equity IPO has generated moderate interest in the grey market, where it is commanding a premium of Rs 30 over the upper issue price of Rs 123 — implying a 24% grey market premium (GMP). The stock is scheduled to list on the BSE SME platform on July investors are required to apply for a minimum of 2,000 Capital Options is the lead manager to the issue, Maashitla Securities is acting as the registrar, and JSK Securities and Services will serve as the market in 2019, Asston Pharmaceuticals specializes in the formulation and export of a wide range of pharmaceutical products, including tablets, capsules, syrups, and company operates across multiple therapeutic categories such as antibiotics, antifungals, analgesics, and nutritional supplements. Its manufacturing facilities are FDA-certified and adhere to stringent quality management IPO proceeds will be used to fund capital expenditure for machinery acquisition (Rs 6 crore), meet incremental working capital requirements (Rs 13 crore), partially repay borrowings (Rs 1 crore), and cover general corporate the company has shown strong momentum. For the year ended March 2025, Asston posted a 62% rise in revenue and a 218% surge in profit after tax compared to the previous company reported a PAT of Rs 4.33 crore on revenue of Rs 25.61 crore.
Time of India
2 days ago
- Business
- Time of India
Asston Pharma SME IPO booked over 32 times on Day 3. Check GMP and other details
The IPO of Asston Pharmaceuticals, a fast-growing exporter of healthcare and pharmaceutical products, has garnered strong investor interest across all categories, with the issue subscribed a massive 32.13 times ahead of its closing on July 11, 2025. Retail investors led the surge, subscribing 37.58 times their allotted quota, followed by high-net-worth individuals (HNIs) at 51.40 times. Qualified institutional buyers (QIBs) also showed strong interest, subscribing 7.98 times — underscoring broad-based confidence in the company's growth trajectory and global expansion plans. The book-built issue is priced in the range of Rs 115 to Rs 123 per share, with a fixed lot size of 1,000 shares. At the upper end of the price band, the IPO aims to raise Rs 27.56 crore entirely through a fresh issue of 22.41 lakh equity shares. The IPO has generated moderate interest in the grey market, where it is commanding a premium of Rs 30 over the upper issue price of Rs 123 — implying a 24% grey market premium (GMP). The stock is scheduled to list on the BSE SME platform on July 16. Retail investors are required to apply for a minimum of 2,000 shares. Sobhagya Capital Options is the lead manager to the issue, Maashitla Securities is acting as the registrar, and JSK Securities and Services will serve as the market maker. Founded in 2019, Asston Pharmaceuticals specializes in the formulation and export of a wide range of pharmaceutical products, including tablets, capsules, syrups, and sachets. The company operates across multiple therapeutic categories such as antibiotics, antifungals, analgesics, and nutritional supplements. Its manufacturing facilities are FDA-certified and adhere to stringent quality management protocols. The IPO proceeds will be used to fund capital expenditure for machinery acquisition (Rs 6 crore), meet incremental working capital requirements (Rs 13 crore), partially repay borrowings (Rs 1 crore), and cover general corporate expenses. Financially, the company has shown strong momentum. For the year ended March 2025, Asston posted a 62% rise in revenue and a 218% surge in profit after tax compared to the previous fiscal. The company reported a PAT of Rs 4.33 crore on revenue of Rs 25.61 crore.
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Asston Pharmaceuticals IPO closes today; subscription rises 26x, GMP at 24%
Asston Pharmaceuticals Day 2 subscription status: The initial public offering (IPO) of healthcare products exporter Asston Pharmaceuticals has received a solid response from investors, as the issue has been subscribed over 26 times on the third and final day of bidding. The SME offering, which opened for public subscription on Wednesday, July 9, has received bids for 38.04 million shares, against 1.6 million shares on offer, leading to a subscription of 26.68 times, according to BSE data at 10:55 AM. The demand was driven by retail investors and non-institutional investors (NIIs), who subscribed to their reserved portion by 33.10 times and 33.7 times, respectively. The qualified institutional buyers (QIBs) portion was subscribed 7.98 times. Asston Pharmaceuticals IPO GMP According to sources tracking unofficial markets, the unlisted shares of Asston Pharmaceuticals were trading at ₹153, commanding a premium of ₹30 or 24.39 per cent compared to the upper end of the price band of ₹115 to ₹123, on Friday, in the grey market. Asston Pharmaceuticals IPO details The company plans to raise ₹27.56 crore through a fresh issue of 2.24 million equity shares. There is no offer for sale (OFS) component. The SME IPO will close for subscription today, July 11, 2025. The basis of the allotment of shares is expected to be finalised on Monday, July 14, 2025. Shares of Asston Pharmaceuticals are scheduled to be listed on the BSE SME platform, tentatively on Wednesday, July 16, 2025. Retail investors can bid for a minimum of two lots consisting of 1,000 shares each, with an investment amount of ₹2,46,000 at the upper price band. The minimum investment required for high-net-worth individuals (HNIs) is ₹3,69,000 for three lots of 3,000 equity shares. Asston Pharmaceuticals IPO registrar Maashitla Securities is the registrar of the issue. Sobhagya Capital Options is the sole book-running lead manager for the issue. Asston Pharmaceuticals IPO objective According to the red herring prospectus (RHP), the company plans to utilise the net issue proceeds for acquiring machinery in the manufacturing unit, meet working capital requirements and repay debt. The remaining funds will be used for general corporate purposes. About Asston Pharmaceuticals Incorporated in 2019, Asston Pharmaceuticals manufactures and exports both pharmaceutical formulations and nutraceutical products in domestic and various African and Asian markets. Currently, the company is involved in the business of manufacturing and marketing tablets, capsules, oral liquids, external preparations (Ointment, Cream, Gel, and Lotion), and oral powder (Sachet, Dry Syrup), etc. The company also manufactures various pharmaceutical products for different marketers on loan license or contract manufacturing basis.
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
Retail investors drive demand for Asston Pharmaceuticals IPO; GMP at 24%
Asston Pharmaceuticals IPO Day 2 subscription status: The initial public offering (IPO) of healthcare products exporter Asston Pharmaceuticals has entered its second day of subscription. The issue has received a decent response from investors so far. As of 1:20 PM on July 10, it was oversubscribed by 6.26 times, receiving bids for 10 million shares against 1.6 million shares on offer. The demand was driven by retail investors, who subscribed to their reserved portion 7.93 times. The non-institutional investors (NIIs) category was subscribed 6.06 times, while the qualified institutional buyers (QIBs) portion was subscribed 3.51 times. Asston Pharmaceuticals IPO GMP today The unlisted shares of Asston Pharmaceuticals were commanding a decent premium in the grey markets on Thursday. Sources tracking unofficial market activities revealed that the company's shares were quoted trading at around ₹153 per share, reflecting a grey market premium (GMP) of ₹30 or 24.4 per cent over the upper end of the issue price of ₹123. Asston Pharmaceuticals IPO details The SME offering, valued at around ₹2.56 crore, comprises an entirely fresh issue of 2.24 million equity shares. It does not have any offer for sale (OFS) component. Asston Pharmaceuticals IPO is available at a price band of ₹115 to ₹123 per share, and a lot size of 1,000 shares. Thus, the investors can bid for a minimum of 1,000 shares and in multiples thereof. A retail investor would require a minimum of ₹2,46,000 to bid for two lots or 2,000 shares of Asston Pharmaceuticals IPO. Asston Pharmaceuticals IPO timeline The public offering will remain available for subscription till Friday, July 11. Following that, the basis of allotment is expected to get finalised on Monday, July 14, with shares getting credited into demat accounts by Tuesday, July 15. Asston Pharmaceutical shares are slated to list on the BSE SME platform tentatively on Wednesday, July 16. Asston Pharmaceuticals IPO registrar, lead manager Maashitla Securities serves as the registrar for the issue of Asston Pharmaceuticals, while Sobhagya Capital Options acts as the sole book-running lead manager for the offering. About Asston Pharmaceuticals Asston Pharmaceuticals is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. The company manufactures tablets, capsules, oral liquid, external preparations, and oral powder, etc. The company also manufactures various pharmaceutical products for different marketers on loan license or on a contract manufacturing basis.
